Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | KDM5C | P41229 | 2/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31418319 | 0.85 | KDM4E (0.64) | KAT6AKDM4EKDM4CALDH1A1MPO | |
| SCHEMBL25003812 | 0.84 | MAP4K4 (0.57) | KAT6AMEN1KMT2AKDM4EKDM5B | |
| SCHEMBL22444365 | 0.83 | KDM4E (0.70) | KDM4EKDM5CKDM5BKDM5AKDM6B | |
| SCHEMBL13702267 | 0.83 | ACACB (0.57) | KAT6AKDM4EKDM5CKDM5BKDM5A | |
| SCHEMBL27828455 | 0.83 | CCNC (0.66) | KAT6AALDH1A1CCNCCDK8HDAC1 | |
| SCHEMBL3711618 | 0.83 | HDAC8 (0.63) | KAT6ACCNCCDK8HDAC1KDM1A | |
| SCHEMBL946431 | 0.81 | ASIC3 (0.55) | KAT6AKDM4EKDM5CKDM5BASIC3 | |
| SCHEMBL29541336 | 0.81 | KDM4C (0.71) | KAT6AKDM4EKDM5CKDM5BKDM5A | |
| SCHEMBL648273 | 0.81 | KDM4C (0.71) | KAT6AKDM4EKDM5CKDM5BKDM5A | |
| SCHEMBL25003821 | 0.81 | HDAC1 (0.64) | MEN1KMT2AKDM4EKDM5BKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
| CN-1826335-A | Process for producing 1,2, 4-triazole compound and intermediate therefor | FUJIYAKUHIN CO LTD (JP) | 2006-08-30 | — | — | CN | disclosed |
| US-20060189811-A1 | Process for producing 1,2,4-triazole compound and intermediate therefor | FUJIYAKUHIN CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1650204-A1 | PROCESS FOR PRODUCING 1,2,4-TRIAZOLE COMPOUND AND INTERMEDIATE THEREFOR | Fujiyakuhin Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | KAT6A 152/4885MEN1 4193/4885KMT2A 4030/4885 |
| US-20060189811-A1 | Process for producing 1,2,4-triazole compound and intermediate therefor | CBR3, XDH, CBR1 | KAT6A 3684/4885MEN1 2862/4885KMT2A 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.